SEMAGLUTIDE
Information
Semaglutide is a synthetic 31-amino-acid polypeptide analogue of the endogenous glucagon-like peptide-1 (GLP-1), belonging to the class of drugs labelled glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
ACTION
A GLP-1 analogue, Semaglutide stimulates the body’s GLP-1 receptors to boost pancreatic insulin secretion in a glucose-dependent manner and reduce glucagon levels, thereby improving glycemic control.
PROTOCOL
Semaglutide Dosage for Weight Loss:
When used for chronic weight management, Semaglutide is be dosed according to the following Wegovy brand prescribing information
The starting dose of 0.25mg; once weekly should be maintained for 4 weeks.
Following the initial four weeks, the weekly dose should be increased based on the following schedule:
500mcg/weekly at weeks 5-8;
1mg/weekly at weeks 9-12;
1.7mg/weekly at weeks 13-16;
2.4mg/weekly at weeks 17 and onward.
Missed doses must be delivered within 5 days.
If the subject cannot tolerate a minimum dose of 1.7mg a week, discontinuation of treatment is advised.